Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: A pharmacokinetic pilot study

AIDS

Volumn 14, Issue 9, 2000, Pages

  Van Heeswijk, Rolf P G ^a,b   Veldkamp, Agnes I ^a   Mulder, Jan W ^b   Meenhorst, Pieter L ^b   Lange, Joep M A ^c   Beijnen, Jos H ^a   Hoetelmans, Richard M W ^a  

^a Dept of Pharmacy and Pharmacology ^*  (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Once daily dose; Pharmacokinetics; Protease inhibitors; Ritonavir; Saquinavir

Indexed keywords

GELATIN; RITONAVIR; SAQUINAVIR;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; STEADY STATE; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RITONAVIR; RNA, VIRAL; SAQUINAVIR;

EID: 0033944230     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200006160-00003     Document Type: Article

References (31)

1. 1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among individuals with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
2. 2. Wit FWNM, van Leeuwen R, Weverling GJ, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999, 179:790-798.
3. 3. Paterson D, Swindells S, Mohr J, et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps. Sixth Conference on Retroviruses and Opportunistic Infections Chicago, January-February 1999 [abstract 92].
4. 4. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999, 13:1099-1107.
5. 5. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990, 150:1881-1884.
6. 6. Moyle G. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. Exp Opin Invest Drugs 1998, 7:413-426.
7. 7. Perry CM, Noble S. Saquinavir soft-gel capsule formulation. A review of its use in individuals with HIV infection. Drugs 1998, 55:461-486.
8. 8. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998, 63:453-464.
9. 9. Florence E, Desmet P, Pelgrom Y, Lacor P, Demonthy J, Colebunders R. IRIS Study: ritonavir/saquinavir versus indinavir in association with NRTI: one year follow-up. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 630].
10. 10. Gill MJ. Safety profile of soft-gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. AIDS 1998, 12:1400-1402.
11. 11. Hoetelmans RMW, Meenhorst PL, Mulder JW, Burger DM, Koks CHW, Beijnen JH. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 1997, 19:159-175.
12. 12. Schapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected individuals. Ann Intern Med 1996, 124:1039-1050.
13. 13. Hoetelmans RMW, Van Heeswijk RPG, Meenhorst PL, Mulder JW, Scheele WA, Beijnen JH. Plasma concentrations of saquinavir determine HIV-1 RNA response over a 48-week period. 12th World AIDS Conference. Geneva, June-July 1998 [abstract 42261].
14. 14. Churchill DR, Pym AS, Babiker AG, Back DJ, Weber JN. Rate of onset of hyperlipidaemia following treatment with ritonavir/saquinavir and correlation with drug levels. Presented at Fourth International Congress on Drug Therapy and HIV Infection. Glasgow, November 1998 [OP 2.5].
15. 15. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Safety 1999, 20:147-169.
16. 16. Heeswijk van RPG, Hoetelmans RMW, Harms R. et al. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1998, 719:159-168.
17. 17. Kurowski M, Müller M, Donath F, Mrozikiewicz M, Möcklinghoff C. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with 'baby-dose' ritonavir. Eur J Med Res 1999, 4:101-104.
18. 18. Barry MG, Merry C, Lloyd J, et al. Variability in trough plasma saquinavir concentrations in HIV individuals - a case for therapeutic drug monitoring. Br J Clin Pharmacol 1998, 45: 501-502.
19. 19. Breilh D, Thuret I, Dumon C, et al. Population pharmacokinetics of ritonavir in 31 HIV-infected infants. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [abstract A114.A,F].
20. 20. Lalezari J, on behalf of the NV15107 Study Group. Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. J AIDS Hum Retrovirol 1998, 19:195-197.
21. 21. Nascimbeni M, Lamotte C, Peytavin G, Farinotti R, Clavel F. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother 1999, 43: 2629-2634.
22. 22. Back D, Jones K, Maher B, Hoggard P. Cellular influx/efflux of protease inhibitors in vitro. Seventh Conference on Retroviruses and Opportunistic Infections. San Fransisco, January-February 2000 [abstract 93].
23. 23. Merry C, Barry M, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected individuals. AIDS 1997, 11:F29-F33.
24. 24. Regazzi MB, Villani P, Maserati R, et al. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1-infected individuals. Br J Clin Pharmacol 1999, 47:379-382.
25. 25. Chaillou S, Durant J, Clevenbergh P, et al. Long term efficacy of saquinavir and ritonavir low dosage in HIV individuals failing combination therapy: correlation of response to treatment with genotypic mutations and pharmacologic data. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection. Lisbon, October 1999 [abstract 565].
26. 26. Cameron DW, Japour A, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999, 13:213-224.
27. 27. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in individuals with virologic evidence of indinavir or ritonavir failure. AIDS 1998, 12:F97-F102.
28. 28. Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in individuals who had previously failed nelfinavir. AIDS 1999, 13:F23-F28.
29. 29. Merry C, Back D, Barry M, et al. Therapeutic drug monitoring of protease inhibitors: what to measure and when? Seventh Conference on Retroviruses and Opportunistic Infections. San Fransisco, January-February 2000 [abstract 104].
30. 30. Saag MS, Kilby M, Ehrensing E, et al. Saquinavir systemic exposure and safety of once daily administration of Fortovase (saquinavir) soft gelatin capsule (FTV) in combination with low dose ritonavir (RTV). 39th Intercience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [abstract A33.A,1].
31. 31. Hsu A, Granneman GR, Witt, G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997, 41:898-905.